GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Short-Term Debt & Capital Lease Obligation

Basilea Pharmaceutica (LTS:0QNA) Short-Term Debt & Capital Lease Obligation : CHF17.5 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Basilea Pharmaceutica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF17.5 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Basilea Pharmaceutica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF111.1 Mil.


Basilea Pharmaceutica Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Basilea Pharmaceutica's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Short-Term Debt & Capital Lease Obligation Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 1.75 124.40 39.46 17.52

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.40 119.32 39.46 39.98 17.52

Basilea Pharmaceutica Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Basilea Pharmaceutica Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica (LTS:0QNA) Business Description

Industry
Traded in Other Exchanges
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines